BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Idenix Pharmaceuticals, Inc. (IDIX) Halts Development of Two Hepatitis C Treatments


2/5/2013 7:45:38 AM

Idenix Pharmaceuticals Inc. (IDIX) is shelving the development of two hepatitis C therapies that had been stopped by U.S. regulators after a competing therapy was linked to heart risks. The Food and Drug Administration put a hold on studies of the company’s nucleotide polymerase inhibitors IDX184 and IDX19368, after safety issues arose while Bristol-Myers Squibb Co. (BMY) tested a hepatitis C therapy in the same family of compounds, called guanosines. Idenix is among companies including Bristol-Myers and Gilead Sciences Inc. (GILD), seeking new therapies for the viral disease that affects as many as 170 million people worldwide. The experimental drugs are designed to be taken as pills with shorter treatment durations and fewer side effects than the current medicines. While Idenix, based in Cambridge, Massachusetts, has found no evidence of severe heart problems with patients on its IDX184, the FDA said the clinical holds would remain in place, the company said today in a statement. Idenix hadn’t begun testing IDX19368 in people when the holds were issued. Idenix said it would stop development of the two drugs and proceed with different versions of nucleotides, called uridines. Proof-of-concept testing of the therapies is planned before July, the company said in its statement.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES